RenovoRx (RNXT) EBITDA Margin (2025 - 2026)
RenovoRx's (RNXT) quarterly EBITDA Margin came in at 368.43% in Q2 2026, up 26617.0% year-over-year from N/an in Q2 2025, and up 40.21% quarter-over-quarter from 616.16% in Q1 2026.
Powered by 
Analysis
RenovoRx (RNXT) EBITDA Margin (2025 - 2026) Analysis & Trends
RenovoRx has disclosed EBITDA Margin across 2 years of filings, most recently posting 368.43% for Q2 2026.
- In Q2 2026, EBITDA Margin rose 26617.0% year-over-year to 368.43%; the TTM figure through Jun 2026 stood at 685.22% (changed N/A YoY), while the FY2025 annual figure was 1113.98%, up 2439765.0% from the prior year.
- EBITDA Margin came in at 368.43% for Q2 2026 at RenovoRx, up from 616.16% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 368.43% in Q2 2026 to a low of 1578.68% in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.71 Bn | 174.10 Bn | 7.27 Bn | 13.44% |
| 2 | Intuitive Surgical | 128.01 Bn | 122.80 Bn | 1.96 Bn | 33.60% |
| 3 | Medtronic | 117.20 Bn | 108.38 Bn | 6.34 Bn | 18.08% |
| 4 | Stryker | 104.00 Bn | 100.53 Bn | 4.50 Bn | 25.18% |
| 5 | Boston Scientific | 63.32 Bn | 62.78 Bn | 3.85 Bn | 21.65% |
| 6 | Edwards Lifesciences | 49.95 Bn | 45.70 Bn | 1.35 Bn | 29.48% |
| 7 | Alcon | 32.88 Bn | 31.43 Bn | 1.68 Bn | 0.40% |
| 8 | Dexcom | 32.27 Bn | 30.33 Bn | 830.00 Mn | 24.33% |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn | 19.15% |
| 10 | RenovoRx | 81.83 Mn | 81.83 Mn | 766,000.00 | -368.43% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -368.43% |
| Mar 31, 2026 | -616.16% |
| Dec 31, 2025 | -1,479.83% |
| Sep 30, 2025 | -1,203.01% |
| Jun 30, 2025 | -634.60% |
| Mar 31, 2025 | -1,578.68% |